Tibolone is not converted by human aromatase to 7α-methyl-17α-ethynylestradiol (7α-MEE): Analyses with sensitive bioassays for estrogens and androgens and with LC-MSMS

Steroids

Volumn 68, Issue 3, 2003, Pages 235-243

  De Gooyer, Marcel E ^a   Oppers Tiemissen, Hendrika M ^a   Leysen, Dirk ^a   Verheul, Herman A M ^a   Kloosterboer, Helenius J ^a  

^a NV ORGANON   (Netherlands)

Author keywords

19 Norsteroids; 7 Methyl ethynylestradiol; Aromatase; ER , ER , AR , PR bioassays; Livial; Steroid; Tibolone (Org OD 14)

Indexed keywords

3ALPHA HYDROXYTIBOLONE; 3BETA HYDROXYTIBOLONE; 7ALPHA METHYL 17ALPHA ETHYNYLESTRADIOL; ANDROGEN; ANDROSTENEDIONE; AROMATASE; ESTRADIOL DERIVATIVE; ESTROGEN DERIVATIVE; ESTRONE; HYDROXYL GROUP; METHYLTESTOSTERONE; NANDROLONE; NORETHISTERONE; ORG 33201; RECOMBINANT ENZYME; STEROID RECEPTOR; TESTOSTERONE DERIVATIVE; TIBOLONE; TRESTOLONE; UNCLASSIFIED DRUG;

ANIMAL CELL; AROMATIZATION; ARTICLE; BIOASSAY; CONTROLLED STUDY; DERIVATIZATION; DRUG ACTIVITY; DRUG EFFECT; DRUG STRUCTURE; ESTROGEN ACTIVITY; HUMAN; IN VITRO STUDY; INCUBATION TIME; ISOMER; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PROTEIN DETERMINATION; STEROID ANALYSIS;

EID: 0037333156     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(02)00184-8     Document Type: Article

References (60)

1. Kloosterboer H.J. Tibolone: a steroid with a tissue-specific mode of action. J. Steroid Biochem. Mol. Biol. 76:2001;231-238.
2. Palacios S. Tibolone: what does tissue specific activity mean? Maturitas. 37:2001;159-165.
3. Lundström E., Christow A., Svane G., Azavedo E., Söderqvist G., Kersemaekers W.et al. Effects of tibolone and a continuous combined HRT regimen on mammographic breast density. Am. J. Obstet. Gynecol. 186:2002;717-726.
4. Tang B., Markiewicz L., Kloosterboer H.J., Gurpide E. Human endometrial 3-beta-hydroxysteroid dehydrogenase/isomerase can locally reduce estrogenic/progestagenic activity ratios of a steroidal drug (Org OD 14). J. Steroid Biochem. Mol. Biol. 45:1993;345-351.
5. Markiewicz L., Gurpide E. In vitro evaluation of estrogenic estrogen: antagonistic and progestagenic effects of a steroidal drug (tibolone) and its metabolites on human endometrium. J. Steroid Biochem. 35:1990;535-541.
6. Christodoulakis G.E., Lanbrinoudaki I.V., Vourtsi A.D., Passoutis K.P., Kelekis D.A., Creatsas G.C. Mammagraphic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study. Menopause. 9:2002;110-116.
7. Visser de J., Coert A., Feenstra H., Vies van der J. Endocrinological studies with (7α, 17α)-17-hydroxy-7-methyl-19-nor-pregn5(10)-en-20-yn-3-one tibolone. Arzneim Forsch. 34:1984;1010-1017.
8. Tax L., Goorisssen E.M., Kicovic P.M. Clinical profile of tibolone. Maturitas. 1(Suppl):1987;3-13.
9. Verhoeven C.H.J., Vos R.M.E., Delbressine L.P.C. The in vivo metabolism of tibolone in animal species. Eur. J. Metabol. Pharmacokin. 27:2002;1-10.
10. Vos R.M.E., Krebbers S.F.M., Verhoeven C.H.J., Delbressine L.P.C. The in vivo human metabolism of tibolone. Drug Metab. Dispos. 30:2002;106-112.
11. de Gooyer M.E., Deckers G.H., Schoonen W.G.E.J., Verheul H.A.M., Kloosterboer H.J. Receptor profiling and endocrine interactions of tibolone. Steroids. 68:2003;21-30.
12. Nelson D.R., Koymans L., Kamataki T., Stegeman J.J., Freyereisen R., Waxman D.J.et al. P450 superfamily: update on new sequences, gene mapping, accession numbers, and nomenclature. Pharmacogenetics. 6:1996;1-42.
13. Brodie A.M.H. Recent advances in studies on estrogen biosynthesis. J. Endocr. Invest. 2:1979;445-460.
14. Ryan J.R. Biochemistry of aromatase: significance to female reproductive physiology. Cancer Res. 42:1982;3342-3344.
15. Osawa Y., Shibata K., Rohrer D., Weeks C., Duax W.L. Letter: reassignment of the absolute configuration of 19-substituted 19-hydroxysteroids and stereomechanism of estrogen biosynthesis. J. Am. Chem. Soc. 97:1975;4000-4002.
16. Brodie H.J., Kripalani K.J., Possanza G.J. Studies on the mechanism of estrogen biosynthesis. Part VI. The stereochemistry of hydrogen elimination at C-2 during aromatization. J. Am. Chem. Soc. 91:1969;1241-1242.
17. Sasano H., Harada N. Intratumoral aromatase in human breast endometrial and ovarian malignancies. Endocrine Rev. 19:1998;593-607.
18. Simpson E.R., Clyne C., Rubin G., Boon W.C., Robertson K., Britt K.et al. Aromatase - a brief overview. Annu. Rev. Physiol. 64:2002;93-127.
19. Tan L., Muto N. Purification and reconstitution properties of human placental aromatase A cytochrome P-450-type monooxygenase. Eur. J. Biochem. 156:1986;243-250.
20. Silberzahn P., Gaillard J.L., Quincey D., Dintinger T., Al-Timimi I. Aromatization of testosterone and 19-nortestosterone by a single enzyme from equine testicular microsomes: differences from human placental microsomes. J. Steroid Biochem. 29:1988;119-125.
21. Dintinger T., Gaillard J.L., Moslemi S., Zwain I., Silberzahn P. Androgen and 19-norandrogen aromatization by equine and human placental microsomes. J. Steroid Biochem. 33:1989;949-954.
22. Amri H., Gaillard J.L., Al-Timimi I., Zilberzahn P. Equine ovarian aromatase: evidence for a species specificity. Biochem. Cell Biol. 71:1993;296-302.
23. Khalil M.W., Chung N., Morley P., Glasier M.A., Armstrong D.T. Formation and metabolism of 5(10)-estrene-3 beta, 17 beta-diol, a novel 19-norandrogen produced by porcine granulosa cells from C19 aromatizable androgens. Biochem. Biophys. Res. Commun. 155:1988;144-150.
24. Raeside J.I., Renaud R.L., Friendship R.M. Aromatization of 19-norandrogens by porcine Leydig cells. J. Steroid Biochem. 32:1989;729-735.
25. Sundaram K., Kumar N., Bardin C.W. 7-Alpha-methyl-19-nortestosterone: an ideal androgen for replacement therapy. Rec. Prog. Hormone Res. 49:1994;373-376.
26. LaMorte A., Kumar N., Bardin C.W., Sundaram K. Aromatization of 7 alpha-methyl-19-nortestosterone by human placental microsomes. J. Steroid Biochem. Mol. Biol. 48:1994;297-304.
27. Dintinger T., Gaillard J.L., Zwain I., Bouhamidi R., Silberzahn P. Synthesis and aromatization of 19-norandrogens in stallion testis. J. Steroid Biochem. 32:1989;537-544.
28. Sheean L.A., Meigs R.A. Inhibitor specificity of the placental microsomal oxidase system responsible for the aromatization of epitestosterone (17-alpha-hydroxy-4-androst-3-one). Steroids. 41:1983;225-241.
29. Tseng L., Tseng J.K., Mann W.J., Chumas J.C., Stone M.L., Mazella J.et al. Endocrine aspects of human uterine sarcoma: a preliminary study. Am. J. Obstet. Gynecol. 155:1986;95-101.
30. Perel E., Daniilescu D., Kharlip L., Blackstein M., Killinger D.W. Steroid modulation of aromatase activity in human cultured breast carcinoma cells. J. Steroid Biochem. 29:1988;393-399.
31. Kuhnz W., Heuner A., Humpel M., Seifert W., Michaelis K. In vivo conversion of norethisterone and norethisterone acetate to ethinyl estradiol in postmenopausal women. Contraception. 56:1997;379-385.
32. Reed M.J., Ross M.S., Lai L.C., Ghilchik M.W., James V.H. In vivo conversion of norethisterone to ethynylestradiol in perimenopausal women. J. Steroid Biochem. Mol. Biol. 37:1990;301-303.
33. Klehr-Bathmann I., Kuhl H. Formation of ethinylestradiol in postmenopausal women during continuous treatment with a combination of estradiol, estriol and norethisterone acetate. Maturitas. 21:1995;245-250.
34. Osawa Y., Yarborough C., Osawa Y. Norethisterone a major ingredient of contraceptive pills is a suicide inhibitor of estrogen synthesis. Science. 215:1982;1249-1251.
35. Covey D.F., Hood W.F., McMullan P.C. Studies of the inactivation of human placental aromatase by 17 alpha-ethynyl-substituted 10-beta-hydroperoxy and related 19-nor steroids. Biochem. Pharmacol. 35:1986;1671-1674.
36. Johnston J.O., Wright C.L., Leeson G.A. Regioselectivity of metabolic activation of acetylynic steroids by hepatic cytochrome P450 isozymes. Steroids. 56:1991;180-184.
37. Yamamoto T., Taumura T., Kitawaki J., Osawa Y., Okada H. Suicide inactivation of aromatase in human placenta and uterine leiomyoma by 5 alpha-dihydronorethindrone, a metabolite of norethindrone, and its effect on steroid-producing enzymes. Eur. J. Endocrinol. 130:1994;634-640.
38. Barbieri P.L., Petro Z., Canick J.A., Ryan K.J. Aromatization of norethindrone to ethinyl estradiol by human placental microsomes. J. Clin. Endocrinol. Metab. 57:1983;299-303.
39. Yamamoto T., Yoshiji S., Yasuda J., Shiroshita K., Kitawaki J., Fujii M.et al. Aromatization of norethindrone to ethynylestradiol in human adult liver. Endocrinol. Jpn. 33:1986;527-531.
40. Yamamoto T., Kitawaki J., Shiroshita K., Urabe M., Sasaki J., Fukuoka M. The conformation of norethindrone aromatization in primairy human hepatocytes by the Vitafiber-II cell culture system. Acta. Obstet. Gyneacol. Jpn. 40:1988;87-89.
41. Wiegeratz I., Sanger N., Kuhl H. Formation of 7alpha-methyl-ethinylestradiol during treatment with tibolone. Menopause. 9:2002;293-295.
42. Thompson R.M., Horning E.C. Aromatization of the A-ring of norethynodrel, a steroidal oral contraceptive, during trimethylsilylation. Steroids Lipid Res. 4:1973;135-142.
43. Geelen J.A.A., Deckers G.H., van der Wardt J.T.H., Loozen H.J.J., Tax L.J.W., Kloosterboer H.J. Selection of 19-(ethyldithio)-androst-4ene-3, 17-dione (ORG 30958): a potent aromatase inhibitor in vivo. J. Steroid Biochem. Mol. Biol. 38:1991;181-188.
44. Mor G., Eliza M., Song J., Wiita B., Chen S., Naftolin F. 17-Methyl testosterone is a competitive inhibitor of aromatase activity in Jar choriocarcinoma cells and macrophage-like THP-1 cells in culture. J. Steroid Biochem. Mol. Biol. 79:2001;239-246.
45. Bodine P.V.N., Harris H.A., Lyttle C.R., Komm B.S. Estrogenic effects of 7α-methyl-17α-ethynylestradiol: a newly discovered tibolone metabolite. Steroids. 67:2002;681-686.
46. Boyd R.A., Zegarac E.A., Posvar E.L., Flack M.R. Minimal androgenic activity of a new oral contraceptive containing norethindrone acetate and granulated doses of ethinylestradiol. Contraception. 63:2001;71-76.
47. Moutos D., Smith S., Zacur H. The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globuline: a randomized trial. Contraception. 52:1995;105-109.
48. Song S., Chen J.K., He M.L., Fotherby K. Effect of some oral contraceptives on serum concentrations of hormone binding globulin and ceruloplasmin. Contraception. 39:1989;389-399.
49. Tafurt C.A., Sobrevilla L.A., de Estrada R. Effect of progestin-estrogen combinations and progestational contraceptives on pituitary gonadotropins. Fertil. Steril. 33:1980;261-266.
50. Carol W., Borner A., Klinger G., Greinke C. Transcortin as an indicator of estrogenic potency in oral contraceptives. Endokrinologie. 75:1980;167-172.
51. van der Vange N., Blankenstein M.A., Kloosterboer H.J., Haspels A.A., Thijssen J.H. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin. Contraception. 41:1990;345-352.
52. Ling W.Y., Johnston D.W., Lea R.H., Bent A.E., Scott J.Z., Toews M.R. Serum gonadotropin and ovarian steroid levels in women during administration of a norethindrone-ethinylestradiol triphasic contraceptive. Contraception. 32:1985;367-375.
53. Carr B.R., Parker C.R. Jr., Madden J.D., MacDonald P.C., Porter J.C. Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment. J. Clin. Endocrinol. Metab. 49:1979;346-349.
54. Kicovic P.M., Cortes-Prieto J., Luisi M., Milojevic S., Franchi F. Placebo-controlled cross-over study of effects of Org OD 14 in menopausal women. Reproduction. 6:1982;81-91.
55. Kicovic P.M. New steroid for the climatric syndrome. Min. Endocr. 14:1989;63-67.
56. Dören M., Rubig A., Coelingh Bennink H.J., Holzgreve W. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil. Steril. 75:2001;554-559.
57. Heger-Mahn D., Entezami M., Schutt B., Kuhnz W., Richert K., Lubbert H. Östrogene Effecte nach 14tägiger Gabe von 006 mg Ethinylestradiol bei postmenopausalen Frauen. Geburtsh. u Frauenheilk. 6:1996;221-225.
58. Helgason S. Estrogen replacement therapy after the menopause. Estrogenicity and metabolic effects. Acta. Obstet. Gynecol. Scan. 107(Suppl):1982;1-29.
59. de Gooyer M.E., Overklift Vaupel Kleyn G.T., Smits K.C., Ederveen A.G.H., Verheul H.A.M., Kloosterboer H.J. Tibolone: a compound with tissue specific inhibitory effects on sulfatase. Mol. Cell Endocrinol. 183:2001;55-62.
60. Chetrite G., Kloosterboer H.J., Pasqualini J.R. Effect of tibolone (Org OD 14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anticancer Res. 17:1997;135-140.